M
Marc H Weiner
Researcher at University of Texas Health Science Center at San Antonio
Publications - 70
Citations - 4844
Marc H Weiner is an academic researcher from University of Texas Health Science Center at San Antonio. The author has contributed to research in topics: Rifapentine & Tuberculosis. The author has an hindex of 36, co-authored 70 publications receiving 4243 citations. Previous affiliations of Marc H Weiner include Murphy Oil & United States Department of Veterans Affairs.
Papers
More filters
Journal ArticleDOI
Three Months of Rifapentine and Isoniazid for Latent Tuberculosis Infection
Timothy R. Sterling,M. Elsa Villarino,Andrey S. Borisov,Nong Shang,Fred M. Gordin,Erin Bliven-Sizemore,Judith Hackman,Carol Dukes Hamilton,Dick Menzies,Amy Kerrigan,Stephen E. Weis,Marc H Weiner,Diane Wing,Marcus Barreto Conde,Lorna Bozeman,C. Robert Horsburgh,Richard E. Chaisson +16 more
TL;DR: The use of rifapentine plus isoniazid for 3 months was as effective as 9 months of isoniaZid alone in preventing tuberculosis and had a higher treatment-completion rate.
Journal ArticleDOI
Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: A randomised clinical trial
Debra Benator,Mondira Bhattacharya,Lorna Bozeman,William J. Burman,Antonino Catanzaro,Richard E. Chaisson,Fred M. Gordin,C. Robert Horsburgh,James Horton,Awal Khan,Christopher J. Lahart,Beverly Metchock,Constance Pachucki,Llewellyn Stanton,Andrew Vernon,M. Elsa Villarino,Cheng Wang Yong,Marc H Weiner,Stephen E. Weis +18 more
TL;DR: Rifapentine once a week is safe and effective for treatment of pulmonary tuberculosis in HIV-negative people without cavitation on chest radiography and clinical, radiographic, and microbiological data help identify patients with tuberculosis who are at increased risk of failure or relapse when treated with either regimen.
Journal ArticleDOI
Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis
Marc H Weiner,Debra Benator,William J. Burman,Charles A. Peloquin,Awal Khan,Andrew Vernon,Brenda E. Jones,Claudia Silva-Trigo,Zhen Zhao,Thomas W. Hodge +9 more
TL;DR: Lower plasma concentrations of rifabutin and, perhaps, isoniazid were associated with ARR failure or relapse in patients with tuberculosis and HIV infection treated with twice-weekly therapy.
Journal ArticleDOI
Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine.
Marc H Weiner,William J. Burman,Andrew Vernon,Debra Benator,Charles A. Peloquin,Awal Khan,Stephen E. Weis,Barbara King,Nina Shah,Thomas W. Hodge +9 more
TL;DR: A drug with consistently greater area under the concentration-time curve than isoniazid may be needed to achieve highly active once-weekly therapy with rifapentine.
Journal ArticleDOI
Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis.
Susan E. Dorman,Payam Nahid,Ekaterina V. Kurbatova,Patrick P. J. Phillips,Kia E Bryant,Kelly E. Dooley,Melissa Engle,Stefan V. Goldberg,Ha T.T. Phan,James Hakim,John L. Johnson,Madeleine Lourens,Neil A. Martinson,Neil A. Martinson,Grace Muzanyi,Kim Narunsky,Sandy Nerette,Nhung Viet Nguyen,Thuong H. Pham,Samuel Pierre,Anne E. Purfield,Anne E. Purfield,Wadzanai Samaneka,Radojka M. Savic,Ian Sanne,Nigel A. Scott,Justin Shenje,Erin Sizemore,Andrew Vernon,Ziyaad Waja,Marc H Weiner,Susan Swindells,Richard E. Chaisson +32 more
TL;DR: In this paper, Rifapentine-based regimens have potent antimycobacterial activity that may allow for a shorter course in patients with drug-susceptible pulmonary tuberculosis.